Peptides for Body Composition & Recomposition Research

Body composition optimisation involves two simultaneous goals: reducing fat mass and maintaining or increasing lean mass. Tirzepatide addresses the fat-loss side through dual GIP/GLP-1 receptor activation, which regulates appetite, enhances insulin sensitivity, and promotes fat oxidation. CJC-1295 and Ipamorelin address the lean-mass side by stimulating natural growth hormone release, which drives protein synthesis, supports muscle maintenance, and further enhances lipolysis. This multi-peptide approach reflects the complexity of body recomposition — no single compound optimally addresses both fat loss and lean mass preservation.

Weight loss simply means reducing total body weight, which often involves losing both fat and muscle. Body recomposition aims to change the ratio of fat to lean tissue — reducing fat while maintaining or building muscle. This distinction is critical because muscle mass drives metabolic rate, functional capacity, and long-term health outcomes. Peptides like CJC-1295 and Ipamorelin help preserve lean tissue by maintaining growth hormone levels during caloric restriction, while Tirzepatide promotes preferential fat loss through metabolic pathway modulation. Research shows this combined approach results in superior body composition outcomes compared to caloric restriction alone.

Tirzepatide is unique as a dual GIP/GLP-1 receptor agonist — it activates two key metabolic hormone pathways simultaneously. GLP-1 agonism reduces appetite and slows gastric emptying, while GIP agonism enhances insulin secretion and may directly promote fat oxidation. Clinical trials have demonstrated that Tirzepatide produces greater body weight reduction and metabolic improvements compared to single-pathway GLP-1 agonists like semaglutide. ORYN offers Tirzepatide in both the standard pen system (10mg, 30-day dosing) and the MediT prefilled weekly pen (40mg) to suit different research protocol requirements.

Growth hormone is one of the most powerful signals for body composition regulation. It stimulates lipolysis (fat breakdown), promotes protein synthesis in muscle tissue, and enhances the utilisation of fatty acids for energy. GH levels decline significantly with age, contributing to the typical pattern of increasing fat mass and decreasing muscle mass. CJC-1295 and Ipamorelin restore more youthful GH secretion patterns through complementary mechanisms — CJC-1295 extends GH release duration while Ipamorelin triggers clean GH pulses without affecting cortisol or prolactin — supporting optimal body composition.